Bronchiolitis Obliterans (BO) Terminated Phase 2 Trials for Bortezomib (DB00188)

Also known as: Bronchiolitis Obliterans / Obliterative Bronchiolitis / Bronchiolitis Obliterans Syndrome (BOS) / Bronchiolitis Obliterans Syndrome / Obliterating fibrous bronchiolitis (disorder) / Bronchiolitis fibrosa obliterans (disorder) / Obliterative bronchiolitis (disorder)

IndicationStatusPhase
DBCOND0116742 (Bronchiolitis Obliterans (BO))Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01163786A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHDTreatment